Who’s Fault Is It Anyway?

Posted by & filed under Accounting Information Systems, Accounting Principles, Advanced Accounting, All Articles, Auditing, Behavioral and Social Issues Related to Accounting, Cost Accounting, Ethical Dilemma, Financial Accounting, Intermediate Accounting, Managerial Accounting, Uncategorized, Video Updates.

According to multiple sources, the popularity of Ozempic, (also known as semaglutide) isn’t rising due to increased rates of diabetes, but instead is being used by individuals as the new “weight loss wonder drug”. Questions: Source: Lovelace, B., L. Dunn, K. Dahlgren. (2023). People with diabetes struggle to find Ozempic as it soars in popularity… Read more »

Monopoly May End Soon!

Posted by & filed under Accounting Information Systems, Accounting Principles, Advanced Accounting, All Articles, Auditing, Behavioral and Social Issues Related to Accounting, Cost Accounting, Ethical Dilemma, Financial Accounting, Income Taxes, Intermediate Accounting, Managerial Accounting, Uncategorized.

According to the New York Times, the curtain is expected to come down next week on a monopoly for the anti-inflammatory medication, Humira, that has generated $114 billion in revenue for AbbVie just since the end of 2016. Questions: Source: Robbins, R. (2023). How a Drug Company Made $114 Billion by Gaming the U.S. Patent… Read more »

Change is coming

Posted by & filed under Accounting Information Systems, Accounting Principles, Advanced Accounting, All Articles, Auditing, Cost Accounting, Ethical Dilemma, Financial Accounting, Fraud Accounting, Income Taxes, Intermediate Accounting, International Accounting, Managerial Accounting, Uncategorized.

Change is coming for a small but blooming corner of the marijuana industry. Questions: 1. What is CBD? 2. Why will regulation change the industry? 3. What are some of the legal grey area with unregulated products? 4. What was the most interesting part of this article for you? Source: Brodwin, E. (2018). There’s a… Read more »

Biotechnology Firm, Amgen, Acquires Anti-cancer Drugs

Posted by & filed under Accounting Principles, Advanced Accounting, All Articles, Auditing, Cost Accounting, Financial Accounting, Financial Reporting and Analysis, Financial Statement Analysis, Fraud Accounting, IFRS, Intermediate Accounting, International Accounting, Managerial Accounting.

Although Amgen is the world’s largest biotechnology company, they have not been in the anti-cancer drug market until now. Amgen, like other drug makers, is trying to refresh aging product lines through the acquisition. Questions: 1. What is the ranking of this takeover of biotechnology firms, in terms of historic purchases? What are examples of… Read more »